Related Experiment Video
Updated: Aug 17, 2026
An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
Published on: February 8, 2019
Gene expression in giant cell myocarditis: Altered expression of immune response genes
Michelle M Kittleson1, Khalid M Minhas, Rafael A Irizarry
1Division of Cardiology, Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD, United States.
Insights
Giant cell myocarditis gene expression reveals immune response pathways. This study identifies T-cell activation genes, offering potential therapeutic targets for this severe heart condition.
Area of Science:
- Cardiovascular Biology
- Molecular Genetics
- Immunology
Background:
- Giant cell myocarditis is a severe, rapidly progressing heart condition with unknown causes and limited treatment options.
- Understanding the molecular mechanisms underlying giant cell myocarditis is crucial for developing effective therapies.
- This study investigates gene expression differences between giant cell myocarditis and healthy heart tissue.
Purpose of the Study:
- To compare gene expression profiles in giant cell myocarditis (GCM) patients versus non-failing hearts.
- To identify key molecular pathways involved in GCM pathogenesis.
- To uncover potential therapeutic targets for GCM.
Main Methods:
- Left ventricular samples from GCM patients and donor hearts were analyzed using Affymetrix U133A microarrays.
- Differential gene expression was determined using statistical analysis (Bonferroni-adjusted p < 0.05, fold change > 2.0).
- Quantitative PCR was used to validate selected gene expression findings.
Main Results:
- 115 differentially expressed genes were identified in GCM, with most showing upregulation.
- Key upregulated genes were associated with immune response, transcriptional regulation, and metabolism.
- Specific T-cell activation genes, including chemokine receptors and ligands, were identified.
Conclusions:
- Gene expression analysis provides new insights into GCM pathogenesis, highlighting the role of T-cell activators (Th1 subset) and immune response genes.
- Findings suggest a link between GCM and immune pathways previously observed in heart failure.
- This research lays the groundwork for identifying novel therapeutic strategies for giant cell myocarditis.
Background:
Giant cell myocarditis is a rapidly progressive and often fatal condition without a clear etiology or treatment. A better understanding of giant cell myocarditis pathogenesis is critical to developing treatments to prevent progression and reverse damage. We compared the gene expression of giant cell myocarditis with that of nonfailing hearts.
Methods:
Left ventricular samples from two giant cell myocarditis patients harvested during ventricular assist device placement and six unused donor hearts were examined using Affymetrix U133A microarrays. Differential gene expression was defined with a Bonferroni-adjusted p value < or = 0.05 from a Student's t-test and an absolute fold change > or = 2.0. Select gene expression was confirmed with quantitative PCR.
Results:
Of 115 differentially expressed genes, most were upregulated in giant cell myocarditis and involved in immune response, transcriptional regulation, and metabolism. T-cell activation genes included chemokine receptor 4; chemokine ligands 5, 9, 13, and 18; interleukin-10 receptor alpha; and beta-2 integrin.
Conclusions:
Gene expression analysis of giant cell myocarditis offers novel insights into its pathogenesis, namely the role of T-cell activators of the Th1 subset and immune response genes previously implicated in heart failure. This forms the basis for future work aimed at defining novel therapeutic targets for giant cell myocarditis.
Related Concept Videos
01:21Myocarditis I: Introduction
01:27Myocarditis II: Clinical Features and Diagnostic Tests